NEW YORK, March 28, 2011 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized and non-invasive cancer diagnostics, today announced that Kapil Dhingra, M.B, B.S., has joined the Exosome Diagnostics Board of Directors.
“I am delighted to join the Board of Exosome Diagnostics at this critical stage in the evolution of the company. Cancer treatment is becoming increasingly personalized. The ability to perform repeated, non-invasive analyses of genetic changes in cancer has the potential to transform the diagnostic and treatment paradigms in oncology. I believe that the technology platform developed by the Exosome Diagnostics team has the potential to uniquely contribute to making this promise a reality.”
Dr. Dhingra, 51, has significant experience transforming oncology therapeutic and diagnostic development programs into products available to physicians and patients. He is currently managing member of KAPital Consulting, a healthcare consulting firm he founded in 2008, which provides oncology-related strategic consulting services to biopharmaceutical companies. From 1999-2008, he served in positions of increasing responsibility at Hoffmann-La Roche, Inc, including vice president, head, Oncology Disease Biology Leadership team and head, Oncology Clinical Development. He also worked as a senior clinical research physician at Eli Lilly. Before and during his tenures at both Eli Lilly and Hoffmann-LaRoche, Dr. Dhingra maintained an active academic career first as an assistant professor at MD Anderson Cancer Center, then as a clinical associate professor at Indiana University School of Medicine and most recently as a clinical affiliate at Memorial Sloan Kettering Cancer Center. Dr. Dhingra also serves on several emerging life science company boards. He received his M.B.,B.S. degrees (equivalent to a U.S. M.D. degree) from the All India Institute of Medical Sciences.
“Dr. Dhingra brings strategic expertise to Exosome, both as a physician researcher and as a leading senior executive in pharmaceutical oncology,” said James McCullough, chief executive officer of Exosome Diagnostics. “His product development experience will be essential in guiding our value creation. Dr. Dhingra was involved as Board member in recent very successful transactions with Micromet and Biovex, two biotechnology companies backed by our venture partners NGN Capital and Forbion Capital Partners.”
About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid based molecular diagnostic tests for use in personalized medicine. Exosomes are shed into all biofluids, including blood, urine, and CSF, forming a stable source of intact, disease-specific nucleic acids. The Company’s proprietary exosome technology makes use of this natural stability to achieve high sensitivity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. The Company is commercializing in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of disease. Exosome Diagnostics’ development program is focused on various biofluids with an advanced lead program in collaboration with the Prostate Cancer Foundation looking at exosomes in spot urine for Prostate Cancer; other programs include exosome detection in CSF for glioblastoma and in blood looking at cancer markers for companion diagnostics. The Company maintains facilities in New York, St. Paul, MN and Munich, Germany. For more information, please visit www.exosomedx.com.
Contact:
James McCullough
Chief Executive Officer
Exosome Diagnostics
(212) 781-1213
james@exosomedx.com
Media Contacts:
Robert Flamm, Ph.D., or David Schull
Russo Partners
(212) 845-4226
robert.flamm@russopartnersllc.com
david.schull@russopartnersllc.com
SOURCE Exosome Diagnostics
